Encompass Health saw its IBD SmartSelect Composite Rating rise to 97 Wednesday, up from 94 the day before.
Discover The 3 Keys To Successful Stock Investing
The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's an important benchmark to look for when looking for the best stocks to buy and watch.
Encompass Health is currently extended beyond a proper buy zone after clearing the 103.83 entry in a cup with handle.
The stock earns a 90 EPS Rating, which means its recent quarterly and annual earnings growth tops 90% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company reported 22% EPS growth. Top line growth came in at 11%, down from 13% in the prior quarter.
Encompass Health earns the No. 2 rank among its peers in the Medical-Outpatient/Home Care industry group. BrightSpring Hlth Svcs is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
